Part 10/Chapter 56/6-min read

Post-Thrombotic Syndrome, Iliocaval Obstruction, Venous Compression, and Deep Venous Reconstruction

Chronic venous reconstruction begins by separating acute thrombus management from established post-thrombotic disease. This chapter frames Villalta-based follow-up, patient selection for iliocaval and iliofemoral stenting, non-thrombotic iliac vein lesion thresholds, use of IVUS and cross-sectional imaging, and the narrow role of open or hybrid deep venous reconstruction.

Edited by Tal M. Hörer MD, PhD · David T. McGreevy MD, PhD·Reviewed ·6 sections · 18 references

Listen to this chapter10 min · AI audio edition · two hostsAI narration

Multidisciplinary board: A board-room discussion with roles, escalation triggers, surveillance, patient goals, and what makes the pathway coherent.

General medical education, not patient-specific advice.

Choose the hosts

Definition and presentation

Post-thrombotic syndrome (PTS) is a chronic clinical state following deep vein thrombosis (DVT). It is defined by a Villalta score of >= 5 on two separate occasions at least 3 months after the acute event . Severe PTS is defined by a score of >= 15 . Early post-DVT swelling is not established scarred iliocaval obstruction and is managed as acute venous thromboembolism.

Presenting features of established chronic iliocaval or iliofemoral obstruction include:

  • Persistent swelling and heaviness
  • Pain and venous claudication
  • Skin changes and hyperpigmentation
  • Functional limitation or venous ulceration

Non-thrombotic iliac vein lesions (including May-Thurner syndrome) present with a similar clinical phenotype of unilateral lower-limb or pelvic venous hypertension, but are caused by extrinsic compression of the iliac vein without prior thrombosis .

Diagnosis and stratification

Clinical evaluation relies on longitudinal Villalta scoring to track symptom severity and response to conservative therapy . Diagnostic assessment excludes superficial, lymphatic, cardiac, renal, medication-related, and musculoskeletal mimics of deep venous hypertension.

Duplex ultrasound identifies reflux, obstruction signals, and residual thrombotic change. When chronic reconstruction is considered, cross-sectional venous imaging and intravascular ultrasound (IVUS) define the obstructed segment, landing zones, inflow, and outflow. IVUS alters stenting decisions compared with venography alone in iliofemoral venous obstruction . For non-thrombotic iliac vein lesions, anatomical compression on cross-sectional imaging does not establish the diagnosis unless accompanied by concordant clinical symptoms of deep venous hypertension .

Medical and conservative management

Acute proximal DVT is managed primarily with anticoagulation to prevent embolism and recurrence. A direct oral anticoagulant is first-line for eligible patients without active cancer, and is preferred over low-molecular-weight heparin bridged to a vitamin K antagonist . Selected patients with unprovoked proximal DVT receive extended anticoagulation if the bleeding risk is acceptable.

Conservative management of chronic post-thrombotic syndrome centres on compression therapy. Although the SOX trial demonstrated that routine application of elastic compression stockings does not prevent the initial development of PTS after a proximal DVT , compression remains the first-line treatment for established PTS symptoms and is recommended for at least 2 years following proximal DVT .

Treatment decision thresholds

The intervention decision separates acute thrombus removal from chronic post-thrombotic reconstruction. In acute proximal DVT, routine pharmacomechanical catheter-directed thrombolysis (PCDT) is not indicated. In the ATTRACT trial, PCDT did not reduce overall PTS at 24 months (47% vs 48%) and increased major bleeding (1.7% vs 0.3%) compared with anticoagulation alone . Thrombus removal is reserved for acute iliofemoral DVT with short symptom duration and acceptable bleeding risk . Phlegmasia cerulea dolens or impending venous gangrene overrides these selective criteria and mandates urgent thrombus removal (catheter-directed thrombolysis or mechanical or pharmacomechanical thrombectomy), with fasciotomy if compartment syndrome supervenes .

Chronic post-thrombotic and non-thrombotic iliofemoral obstructions are managed by stenting or open reconstruction only when conservative therapy fails and symptoms align with anatomically suitable disease. Indiscriminate stenting of asymptomatic imaging findings is not indicated .

The management pathway follows an ordered sequence:

  1. Treat acute VTE medically with anticoagulation.
  2. Evaluate acute iliofemoral DVT for selective early thrombus removal based on symptom duration and bleeding risk.
  3. Institute a trial of compression and conservative care for post-thrombotic symptoms.
  4. Select patients with severe, refractory symptoms for chronic endovascular stenting or open reconstruction.
  5. Pursue no intervention for asymptomatic anatomic compression.
Decision threshold

Venous intervention and reconstruction thresholds

  1. Acute proximal DVT (femoral-popliteal)
    Acute presentation, standard bleeding risk
    Medical therapy alone (anticoagulation); no routine lysis
  2. Acute iliofemoral DVT
    Short duration, acceptable bleeding risk, severe symptoms
    Consider catheter-directed or pharmacomechanical thrombus removal
  3. Phlegmasia cerulea dolens or impending venous gangrene
    Limb threat, any symptom duration
    Urgent thrombus removal (thrombolysis or mechanical/pharmacomechanical thrombectomy); fasciotomy for compartment syndrome
  4. Asymptomatic iliac compression
    Non-thrombotic lesion on imaging, no symptoms
    No intervention; continued observation
  5. Chronic post-thrombotic syndrome
    Villalta score >= 5, adequately controlled by compression
    Continue conservative management
  6. Severe chronic iliocaval or iliofemoral obstruction
    Severe symptoms refractory to compression; adequate inflow and outflow
    Endovascular stenting evaluation
Source · · · · ·

Endovascular and open reconstruction

Stenting is the preferred intervention for severe, symptomatic chronic iliofemoral and iliocaval obstruction refractory to compression therapy. The technical success of venous stenting depends on adequate inflow, a clear outflow target, and IVUS-guided sizing . The ABRE study, a prospective pivotal study of the Abre venous stent, supports the safety and patency of modern dedicated venous stents in symptomatic outflow obstruction . ABRE enrolled 200 patients across post-thrombotic, non-thrombotic, and acute presentations and reported 12-month primary patency of 88.0%. However, the evidence base remains predominantly observational; a 2025 Cochrane review of stenting versus anticoagulation alone for DVT-related obstruction identified only two randomized trials (134 participants) and found that while secondary occlusion may be reduced at 24 months (RR 0.26), the certainty of evidence for PTS prevention and quality of life is very low .

Open or hybrid deep venous reconstruction, including deep venous reflux correction, is reserved for specialized cases where the obstruction or reflux anatomy is not amenable to standard endovascular stenting and symptoms remain severe .

Areas of controversy

The magnitude of benefit for early thrombus removal in acute iliofemoral DVT remains contested. While the CaVenT trial demonstrated that additional conventional catheter-directed thrombolysis reduced PTS at 5 years from 71% to 43% (absolute risk reduction 28%, number needed to treat approximately 4) , the CAVA trial (using ultrasound-accelerated lysis) did not show a statistically significant reduction at 12 months (29% vs 35%) . Furthermore, the ATTRACT iliofemoral subgroup demonstrated improvements only in moderate-to-severe PTS (18% vs 28%) rather than overall incidence .

High-quality randomized data comparing venous stenting to conservative care in established post-thrombotic syndrome are sparse. Current consensus recommendations rely heavily on observational cohort data and device-specific trials rather than large controlled trials .

The exact degree of anatomical compression and symptom severity required to justify stenting in non-thrombotic iliac vein lesions is not uniformly established, leaving the intervention threshold highly reliant on clinical judgment regarding symptom concordance .

References

  1. 1.
    Guidance for the prevention and treatment of the post-thrombotic syndrome. 2016.
    PubMed-indexed articleClinical practice guideline2016

    Guidance for the prevention and treatment of the post-thrombotic syndrome. 2016. doi:10.1007/s11239-015-1312-5.

    PubMedDOIOpen PDF
  2. 2.
    ESVS 2022 Clinical Practice Guidelines on Chronic Venous Disease of the Lower Limbs DOI: 10.1016/j.ejvs.2021.12.024
    PubMed-indexed articleClinical practice guideline2022
    PubMedDOI
  3. 3.
    Consensus Statement on the Management of Nonthrombotic Iliac Vein Lesions From the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society. 2024.
    PubMed-indexed articleClinical practice guideline2024

    Consensus Statement on the Management of Nonthrombotic Iliac Vein Lesions From the VIVA Foundation, the American Venous Forum, and the American Vein and Lymphatic Society. 2024. doi:10.1161/CIRCINTERVENTIONS.124.014160.

    PubMedDOIOpen PDF
  4. 4.
    Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. 2017.
    PubMed-indexed article2017

    Venography versus intravascular ultrasound for diagnosing and treating iliofemoral vein obstruction. 2017. doi:10.1016/j.jvsv.2017.04.007.

    PubMedDOI
  5. 5.
    Society of Interventional Radiology Position Statement on the Management of Chronic Iliofemoral Venous Obstruction with Endovascular Placement of Metallic Stents. 2023.
    PubMed-indexed articleClinical practice guideline2023

    Society of Interventional Radiology Position Statement on the Management of Chronic Iliofemoral Venous Obstruction with Endovascular Placement of Metallic Stents. 2023. doi:10.1016/j.jvir.2023.06.013.

    PubMedDOI
  6. 6.
    Antithrombotic Therapy for VTE Disease. 2021.
    PubMed-indexed articleClinical practice guideline2021

    Antithrombotic Therapy for VTE Disease. 2021. doi:10.1016/j.chest.2021.07.055.

    PubMedDOI
  7. 7.
    Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. 2021.
    PubMed-indexed articleClinical practice guideline2021

    Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. 2021. doi:10.1016/j.ejvs.2020.09.023.

    PubMedDOI
  8. 8.
    Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. 2014.
    PubMed-indexed articleRandomized controlled trial2014

    Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. 2014. doi:10.1016/S0140-6736(13)61902-9.

    PubMedDOI
  9. 9.
    Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. 2017.
    PubMed-indexed articleRandomized controlled trial2017

    Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. 2017. doi:10.1056/nejmoa1615066.

    PubMedDOI
  10. 10.
    Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. 2019.
    PubMed-indexed articleRandomized controlled trial2019

    Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. 2019. doi:10.1161/circulationaha.118.037425.

    PubMedDOI
  11. 11.
    CaVenT 5-year: post-thrombotic syndrome after catheter-directed thrombolysis for DVT (2016) DOI: 10.1016/s2352-3026(15)00248-3
    PubMed-indexed articleRandomized controlled trial2016
    PubMedDOI
  12. 12.
    Thrombolysis for acute deep vein thrombosis. 2016.
    PubMed-indexed articleMeta-analysis / systematic review2016

    Thrombolysis for acute deep vein thrombosis. 2016. doi:10.1002/14651858.cd002783.pub4.

    PubMedDOI
  13. 13.
    Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. 2007.
    PubMed-indexed articleRegistry / cohort2007

    Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic result. 2007. doi:10.1016/j.jvs.2007.06.046.

    PubMedDOI
  14. 14.
    Pivotal Study Evaluating the Safety and Effectiveness of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction. 2022.
    PubMed-indexed articleRegistry / cohort2022

    Pivotal Study Evaluating the Safety and Effectiveness of the Abre Venous Self-Expanding Stent System in Patients With Symptomatic Iliofemoral Venous Outflow Obstruction. 2022. doi:10.1161/CIRCINTERVENTIONS.121.010960.

    PubMedDOIOpen PDF
  15. 15.
    Angioplasty or stenting for deep venous thrombosis (Cochrane 2025) DOI: 10.1002/14651858.CD011468.pub2
    PubMed-indexed articleMeta-analysis / systematic review2025
    PubMedDOIOpen PDF
  16. 16.
    Systematic review and meta-analysis of deep venous reflux correction in chronic venous insufficiency. 2023.
    PubMed-indexed articleMeta-analysis / systematic review2023

    Systematic review and meta-analysis of deep venous reflux correction in chronic venous insufficiency. 2023. doi:10.1016/j.jvsv.2023.07.003.

    PubMedDOI
  17. 17.
    CAVA trial: ultrasound-accelerated CDT versus anticoagulation for PTS prevention (2020) DOI: 10.1016/s2352-3026(19)30209-1
    PubMed-indexed articleRandomized controlled trial2020
    PubMedDOI
  18. 18.
    Editor's Choice - A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction. 2016.
    PubMed-indexed articleReview2016

    Editor's Choice - A Systematic Review of Endovenous Stenting in Chronic Venous Disease Secondary to Iliac Vein Obstruction. 2016. doi:10.1016/j.ejvs.2015.09.002.

    PubMedDOI

Educational use only

AI assists this editorial workflow. Published updates are human-reviewed before publication.

Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.

Verify clinically relevant information against primary sources and current guidelines.

AI DisclosurePrivacyTermsCautions